The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2022 | Identification and targeting of rare genomic alterations in metastatic CRC
Heinz-Josef Lenz, MD, University of Southern California, Los Angeles, CA, talks on the use of next-generation sequencing (NGS) and RNA sequencing (RNA-Seq) to identify the molecular makeup of colorectal cancer (CRC). The potential to target rare genomic alterations present in metastatic CRC, for instance NTRK fusions, is discussed. Moreover, Prof. Lenz comments on the development of KRAS-G12C and KRAS-G12D inhibitors and the discrepancies in success rates of using these drugs for the treatment of other cancers, such as non-small cell lung cancer (NSCLC), compared to colorectal cancer (CRC). This interview took place at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO WCGIC) 2022 in Barcelona, Spain.
Disclosures
Ad Boards/Lectures: BMS, Roche, Oncocyte, Fulgent, Bayer, G1 Therapeutics, Jazz Therapeutics, Abbvie, Merck, Merck KG, Isofol
Clinical Trial Support: NCI, NIH, SWOG, Isofol, Pfizer, BMS, G1 Therapeutics, Cardiff, Amal-KISIMA, Mirati, Merck, Bayer, Idera, UCB, PsOxius, NGM, OBI Pharma
